Reuters
Tamoxifen and
raloxifene drugs revolutionized breast cancer care about10 years ago, helping to
reduce the risk of breast cancer for many women world-wide. During this time
Penn has played an active part in researching how effective these drugs are and
discovering their differences. A recent study, lead by Angela DeMichele, MD, MSCE, Abramson Cancer
Center oncologist and assistant professor of Medicine and Epidemiology, and
published in the September issue of the Journal of Clinical Oncology, was featured
in Reuter’s, HealthDay, and MSN.com. Dr. DeMichele and colleagues
found that while raloxifene and tamoxifen are similarly effective in reducing
breast cancer risk, raloxifene also appears to offer the added benefit of
reducing the risk of endometrial cancer. These results are important, says Dr.
DeMichele, “because they suggest a critical difference between tamoxifen and
raloxifene that could help physicians in tailoring therapy to the patient.
View Full Article
View MSN Article
Find a Doctor/Researcher
Make an Appointment
Refer a Patient
Make a Gift
Penn Cancer Network
